Disease activity index

Fig. 1. Pouchitis Disease Activity Index (PDAI) score changes before and after antibiotic therapy in patients with chronic, treatment-resistant pouchitis (from Gionchetti et al. [50]).

Finally, Shafran et al. [52] presented recently an open-label study on the efficacy and safety of rifaximin 600 mg/ day for 16 weeks in the treatment of mildly to moderately active CD. At the end of the study, 59% of patients were in remission (as defined by a Crohn s Disease Activity Index, CDAI, <150) with a significant reduction of the... 

Adults - Take 9 mg once daily in the morning for up to 8 weeks. Swallow capsules whole do not chew or break. For recurring episodes of active Crohn disease, a repeat 8-week course of budesonide can be given. Following an 8-week course of treatment for active disease and once the patient s symptoms are controlled (Crohn Disease Activity Index less than 150), budesonide 6 mg is recommended once daily for maintenance of clinical remission for up to 3 months. If symptom control is still maintained at 3 months, an attempt to taper to complete cessation is recommended. Continued treatment with budesonide 6 mg for more than 3 months has not been shown to provide substantial clinical benefit. 

NSAID-refractory-AS is defined when after treatment with at least 2 different NS AID over a period of at least 2 months, ASAS 20 is not obtained, and ESR, CRP, and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score do not improve, or worsens versus baseline. Indications for therapy with SBC-5-IMNs are in NSAID-refractory AS with ESR > 40 mm and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) > 4. Less than 5% of patients with NSAID-refractory AS in the community at large fulfill these conditions. Remission is defined when ESR and VAS have declined to <10 mm (men <5 mm) and the disease activity scores are <1 (scale 0-10). Remission with oral drugs is defined when remission is maintained with oral drugs for at least 2 years. Remission without drugs is defined when remission without drugs is sustained without relapse for at least 2 years. 

E. Therapeutic response The safety and efficacy of a single intravenous dose of Remicade were assessed in a randomized, double-blind, placebo-controlled study of patients with moderate to severe active Crohn s disease who had failed standard therapy. The primary end point was the proportion of patients who experienced a clinical response, defined as a minimum decrease in the Crohn s Disease Activity Index from baseline at the 4-week evaluation and without an increase in Crohn s... 

Based upon these observations and following Phase I safety studies, a Phase II randomized, double-blind, controlled clinical trial was undertaken to treat active ulcerative colitis with escalating doses of ISIS 2302. Based on an intent-to-treat analysis, 59% (13/22) of patients treated daily with 240 mg ISIS 2302 enema over six weeks achieved a positive response, as measured by Disease Activity Index (DAI)... 

In the study of SLE patients, we and other authors have found that there is a correlation between SLE disease activity index (SLEDAI) and the production of IL-16 (L7) and IL-18 (W19). It was suggested that IL-16 and IL-18 may be a useful indicator of disease activity of SLE. Plasma MCP-1 concentration has also been proposed as a marker for monitoring joint inflammation in rheumatoid arthritis (El). 

Other methods of clearing autoantibodies are extracorporeal and use the im-munoadsorption principle. Hollow fibers with dextran sulfate-coated cellulose membranes can adsorb pathogenic anti-DNA subgroups of high avidity and/or cationic antibodies, anticardiolipin, and anaphylatoxins (S35). The SLE disease activity index significantly decreased after such treatment (S35). However, the indication is still controversial. 

In a randomized, multicenter study in 94 patients, mesalazine 4 g/day for 12 weeks in a microgranular formulation was as effective as a standard dose of a glucocorticoid (6-methylpredisolone 40 mg/day) in mild to moderate Crohn s ileitis (Crohn s Disease Activity Index 180-350) (9). The group treated with methylpredisolone had a higher number of adverse events than those given mesalazine. The only adverse effect related to mesalazine was acute pancreatitis, which resolved on withdrawal. 

Systemic lupus erythematosus Single-center experience, double-blind, randomized, controlled trial 24 weeks Leflunomide 100 mg/day for 3 days, then 100 mg/day n = 6) versus placebo n = 6) Disease activity fell significantly in both groups after 6 months, and the reduction in SLE disease activity index from baseline to 24 weeks was significantly greater with leflunomide than with placebo (29)... 

Best WR, Becktel JM, Singleton JW. Development of a Crohn s disease activity index. Gastroenterology 1976 70 439M4. 

The severity of ulcerative colitis may be assessed by factors such as stool frequency, presence of blood in stool, fever, pulse, hemoglobin, erythrocyte sedimentation rate, C-reactive protein, abdominal tenderness, and radiologic or endoscopic findings. The severity of Crohn s disease can be assessed by the Crohn s disease activity index, which includes stool frequency, presence of blood in stool, endoscopic appearance, and physician s global assessment. 

Systemic Lupus Activity Measure (SLAM)/Revised SLAM (SLAM-R) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)... 

The clinical significance of the degree of bowel wall thickening in known CD patients is controversial. Several studies attempted to establish a relationship between maximum bowel wall thickness and clinical (Crohn s disease activity index, CDAI) and biochemical (erythrocyte sedimentation rate, C reactive protein) parameters of CD activity. However, almost all the results of these studies produced weak corre-... 

Observational studies The efficacy of pulse pamidronate therapy in NSAID-refractory active ankylosing spondylitis has been assessed in 52 patients using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 47 completed the study [9 ]. They were given an NSAID and monthly intravenous infusions of pamidronate 60 mg for 6 months. The most common adverse reactions were arthralgia and myalgia, in 11 cases each, after the initial infusions. There were five withdrawals two defaults, one for a hip joint replacement, and two because of asymptomatic rises in serum creatinine. 

In an observational study, 95 patients with Crohn disease activity index <150 were randomly assigned to 6-mercaptopurine (0.5-1.5mg/kg/day, n=30), Elental as an elemental diet (>900kcal/day,... 

---